Fig. 3
From: The EEF1A2 gene expression as risk predictor in localized prostate cancer
In silico validation of EEF1A2 a) Reanalysis of the microarray dataset by Taylor et al. revealed EEF1A2 to be overexpressed in 16.9% of localized PCA and in 52.6% of metastatic PCa (dashed line indicates an expression z-score of 2 compared to benign tissue). b) EEF1A2 overexpression was grade dependent in localized PCa and highest in metastases. c) Localized tumors with high EEF1A2 expression (indicated by a red square in b) had a significantly shorter biochemical recurrence-free survival